AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2021

Aug 25, 2021

29977_dirs_2021-08-25_c7e08e21-0ad2-4b21-8f35-45396d4f101a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-20

Reporting Person: Fenimore Christopher R. (SVP Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-20	Common Stock	F	8719	$664.85	Disposed	19020	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The amount of securities shown following the reported transaction gives effect to the other transactions reported by the Reporting Person in the Original Form 4.